Literature DB >> 21570203

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.

Jun Won Kim1, Jinsil Seong, Mijin Yun, Ik Jae Lee, Hong In Yoon, Ho Jin Cho, Kwang-Hyub Han.   

Abstract

PURPOSE: To assess the significance of the ratio between standardized uptake values (SUV) of tumor and normal liver tissue obtained from positron emission tomography with fluorine-18-fluorodeoxyglucose (FDG-PET) in predicting the response of hepatocellular carcinoma (HCC) patients treated with external beam radiotherapy (EBRT). METHODS AND MATERIALS: We retrospectively analyzed 35 HCC patients who were treated with EBRT between January 2004 and June 2007. All patients underwent FDG-PET in which SUV values were obtained from tumor and normal liver tissues and were used to calculate the ratios (SUV(Tumor)/SUV(Liver)). After FDG-PET, patients received liver treatment including concurrent chemoradiation, transarterial chemoembolization plus RT, or intraarterial chemotherapy plus RT. Using three-dimensional conformal RT, median dose of 45 Gy was delivered in conventional fractions. Patients underwent abdominal/pelvic CT 1 month after RT, and treatment responses were evaluated according to the Response Evaluation Criteria in Solid Tumors criteria.
RESULTS: Patients were divided into high-SUV ratio group (n = 20) and low-SUV ratio group (n = 15) according to SUV ratio at a cutoff value of 2.5. Objective responses consisting of either complete response (CR) or partial response (PR) were observed in 16 and 6 patients (46% vs. 17%, p = 0.015), respectively; median survivals after RT were 8 months and 5 months (p = 0.41) for the high-SUV ratio group and the low-SUV ratio group, respectively. Rates of intrahepatic metastases (9% vs. 11%, p = 0.39) and distant metastases (32% vs. 32%, p = 0.27) showed no significant difference between two groups.
CONCLUSIONS: External beam RT for HCC patients with higher SUV ratios resulted in higher response rates than for patients with lower SUV ratios. Treatment of HCC with higher SUV ratios did not result in increased survival; high rates of intrahepatic and distant metastases in both SUV groups may have affected patient survival. SUV ratios from pre-RT FDG-PET may be beneficial for selecting patients who are likely to respond to EBRT for unresectable HCC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570203     DOI: 10.1016/j.ijrobp.2010.11.076

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.

Authors:  Wong Hoi She; Tan To Cheung; Thomas C C Yau; Albert C Y Chan; Kenneth S H Chok; Ferdinand S K Chu; Rico K Y Liu; Ronnie T P Poon; See Ching Chan; Sheung Tat Fan; Chung Mau Lo
Journal:  Hepatobiliary Surg Nutr       Date:  2014-08       Impact factor: 7.293

2.  Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma.

Authors:  In Young Jo; Seok-Hyun Son; Myungsoo Kim; Soo Yoon Sung; Yong Kyun Won; Hye Jin Kang; So Jung Lee; Yong-An Chung; Jin Kyoung Oh; Chul-Seung Kay
Journal:  Radiat Oncol J       Date:  2015-09-30

3.  Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis.

Authors:  Jinhong Jung; Moonkyoo Kong; Seong Eon Hong
Journal:  Onco Targets Ther       Date:  2014-09-26       Impact factor: 4.147

Review 4.  Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.

Authors:  Valerie J W Tong; Vishal G Shelat; Yew Kuo Chao
Journal:  J Clin Transl Res       Date:  2021-11-06

5.  The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).

Authors:  Wenhui Ma; Jia Jia; Shengjun Wang; Wei Bai; Jingwei Yi; Ming Bai; Zhiyong Quan; Zhanxin Yin; Daiming Fan; Jing Wang; Guohong Han
Journal:  Theranostics       Date:  2014-05-01       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.